Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 2, 2025
Join us for The Son-Rise Program® In-Person Start-Up
EIN Presswire
·
April 2, 2025
Autism Treatment Center of America® announces The Son-Rise Program® In-Person Start-Up in Sheffield, Massachusetts, June 23rd - 27th. SHEFFIELD, MA, UNITED STATES, April 2, 2025 /EINPresswire.com/ -- The Son-Rise Program, a transformative approach to …
Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure
GlobeNewswire
·
April 2, 2025
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug Administration (FDA) …
America’s VetDogs Supports Introduction of the Service Dogs Assisting Veterans Act
GlobeNewswire
·
April 2, 2025
Washington, DC, and Smithtown, NY, April 02, 2025 (GLOBE NEWSWIRE) -- America's VetDogs, a leading national nonprofit provider of service dogs to veterans, active-duty service members, and first responders with disabilities, today joined Congressman Morgan …
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 2, 2025
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the …
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 2, 2025
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for …
Range Impact Announces Major Land Acquisition in West Virginia
GlobeNewswire
·
April 2, 2025
CLEVELAND, OHIO, April 02, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing distressed coal mines throughout Appalachia, today announced the …
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
GlobeNewswire
·
April 2, 2025
Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer Disciplined financial strategy toward long- …
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers de l’exercice 2024
GlobeNewswire
·
April 2, 2025
Le programme de développement global de JNJ-1900 (NBTXR3) progresse comme prévu, avec l’opportunité d’adresser l’un des plus grands marchés inexploités en oncologie grâce aux programmes les plus avancés dans le cancer de la tête et du cou et le cancer du …
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
GlobeNewswire
·
April 2, 2025
Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus on developing commercial opportunities, spin-outs, joint- …
ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®
GlobeNewswire
·
April 2, 2025
PORTLAND, Maine, April 02, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025
GlobeNewswire
·
April 2, 2025
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange …
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
GlobeNewswire
·
April 2, 2025
WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the …
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 2, 2025
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. FibroGen’s management team will be …
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
GlobeNewswire
·
April 2, 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the …
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 2, 2025
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase …
GRI Bio Announces Closing of $5.0 Million Public Offering
GlobeNewswire
·
April 2, 2025
LA JOLLA, CA, April 02, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and …
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
GlobeNewswire
·
April 2, 2025
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial …
eXoZymes Provides Fourth Quarter and Full Year 2024 Update
GlobeNewswire
·
April 2, 2025
Management to Host Conference Call Today at 4:30PM Eastern Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential …
NeuroPace Announces Refocusing of Product Portfolio
GlobeNewswire
·
April 2, 2025
-- Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 -- -- Maintaining 2025 Revenue Guidance -- -- No Change to Long-Range Plan Expectations of Cash Flow Breakeven by the end of 2027 and Achievement of 20%+ Revenue CAGR -- …
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
·
April 2, 2025
FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious …